Keywords: cladribine, enters, trial, patients, risk, ms, merck

Cladribine enters trial in patients at risk of MS

Article | 29 September 2008

Print This

Merck Serono, a division of Germany's Merck KGaA, has initiated a Phase III trial to evaluate the therapeutic effects of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in